Complement activation in multiple sclerosis plaques: an immunohistochemical analysis
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Inflammation and complement activation are firmly implicated in the pathology of multiple sclerosis; however, the extent and nature of their involvement in specific pathological processes such as axonal damage, myelin loss and disease progression remains uncertain. This study aims to bring clarity to these questions. RESULTS: We describe a detailed immunohistochemical study to localise a strategically selected set of complement proteins, activation products and regulators in brain and spinal cord tissue of 17 patients with progressive multiple sclerosis and 16 control donors, including 9 with central nervous system disease. Active, chronic active and chronic inactive multiple sclerosis plaques (35 in total) and non-plaque areas were examined.Multiple sclerosis plaques were consistently positive for complement proteins (C3, factor B, C1q), activation products (C3b, iC3b, C4d, terminal complement complex) and regulators (factor H, C1-inhibitor, clusterin), suggesting continuing local complement synthesis, activation and regulation despite the absence of other evidence of ongoing inflammation. Complement staining was most apparent in plaque and peri-plaque but also present in normal appearing white matter and cortical areas to a greater extent than in control tissue. C1q staining was present in all plaques suggesting a dominant role for the classical pathway. Cellular staining for complement components was largely restricted to reactive astrocytes, often adjacent to clusters of microglia in close apposition to complement opsonised myelin and damaged axons. CONCLUSIONS: The findings demonstrate the ubiquity of complement involvement in multiple sclerosis, suggest a pathogenic role for complement contributing to cell, axon and myelin damage and make the case for targeting complement for multiple sclerosis monitoring and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724 · cited 1×
“There is on-going debate surrounding the contribution of inflammation to the relentless axonal degeneration seen in MS patients, clinically most apparent in progressive disease; absence of immune cells and lack of efficacy of anti-inflammatories has led some to postulate a complex and as yet undefined neurodegenerativ…”
Backgroundvon Büdingen, H.-C., Palanichamy, A., Lehmann-Horn, K., Michel, B. A., & Zamvil, S. S. (2015) · European Neurology · doi:10.1159/000377675 · Cited by 1,463
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182 · cited 1×
“Introduction Multiple sclerosis (MS) is a chronic neuroinflammatory disease characterised by well demarcated white matter (WM) plaques of demyelination with varying degrees of axonal loss [1].”
BackgroundAcute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation
Bitsch, A. (2000) · Brain · doi:10.1093/brain/123.6.1174 · Cited by 898 · cited 1×
“Numerous immunohistochemistry studies described the presence of complement proteins in and around areas of pathology in MS WM; however, analyses were generally limited to one or a few complement proteins and small numbers of cases [7-13].”
BackgroundCerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report.
Andersson, M., Alvarez-Cermeno, J., Bernardi, G., Cogato, I., Fredman, P., Frederiksen, J., Fredrikson, S., Gallo, P., Grimaldi, L. M., Gronning, M., et al. (1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.8.897 · Cited by 741 · cited 1×
“Immune complexes were demonstrated in MS CSF and brain with associated binding of C1q and classical pathway activation [22]; in parallel, it was shown that oligoclonal immunoglobulins were present in CSF in most MS patients [23], the result of intrathecal synthesis [24].”
BackgroundDistinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis
Lucchinetti, C. F., Brück, W., Rodriguez, M., & Lassmann, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00854.x · Cited by 733 · cited 2×
“Pathological heterogeneity and heterogeneity of complement staining in MS lesions was described by Lucchinetti and colleagues; they proposed four distinct patterns of MS lesions with only 50% of patients showing complement immunolabelling, limited in their study to TCC immunolabelling using the mAb B7, also used in ou…”
BackgroundMethodImmunopathology of secondary‐progressive multiple sclerosis
Prineas, J. W., Kwon, E. E., Cho, E., Sharer, L. R., Barnett, M. H., Oleszak, E. L., Hoffman, B., & Morgan, B. P. (2001) · Annals of Neurology · doi:10.1002/ana.1255 · Cited by 453 · cited 2×
“A notable exception was a study by Prineas who showed abundant C3d deposition on myelin in areas of pathology and suggested a direct role as an opsonin driving immune response to myelin antigens [9].”
BackgroundSelf-citationMultiple sclerosis: In situ evidence for antibody‐ and complement‐mediated demyelination
Storch, M. K., Piddlesden, S., Haltia, M., Iivanainen, M., Morgan, P., & Lassmann, H. (1998) · Annals of Neurology · doi:10.1002/ana.410430409 · Cited by 422 · cited 1×
“Numerous immunohistochemistry studies described the presence of complement proteins in and around areas of pathology in MS WM; however, analyses were generally limited to one or a few complement proteins and small numbers of cases [7-13].”
BackgroundHomogeneity of active demyelinating lesions in established multiple sclerosis
Breij, E. C. W., Brink, B. P., Veerhuis, R., van den Berg, C., Vloet, R., Yan, R., Dijkstra, C. D., van der Valk, P., & Bö, L. (2008) · Annals of Neurology · doi:10.1002/ana.21311 · Cited by 353 · cited 4×
“[11] described myelin staining for C3d but not TCC in active lesions.”
BackgroundInfluentialComplement components of the innate immune system in health and disease in the CNS
Gasque, P., Dean, Y. D., McGreal, E. P., VanBeek, J., & Morgan, B. P. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)80302-1 · Cited by 343 · cited 1×
“In ischaemic infarction there is catastrophic blood brain barrier (BBB) disruption, facilitating entry of complement; in MS, Alzheimer’s disease and encephalitis where the degree of BBB disruption is uncertain, local synthesis may be an important contributor and it is known that glial cells can produce all complement…”
BackgroundSelf-citationQin, Y., Duquette, P., Zhang, Y., Talbot, P., Poole, R., & Antel, J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3568 · Cited by 320 · cited 1×
“Immune complexes were demonstrated in MS CSF and brain with associated binding of C1q and classical pathway activation [22]; in parallel, it was shown that oligoclonal immunoglobulins were present in CSF in most MS patients [23], the result of intrathecal synthesis [24].”
BackgroundAstrocytes in multiple sclerosis: A product of their environment
Nair, A., Frederick, T. J., & Miller, S. D. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8059-5 · Cited by 313 · cited 1×
“The notion of astrocytes contributing to pathological process in MS by enhancement of immune response and disruption of myelin has recently been raised in a number of studies [30,31].”
Weiner, H. L. (2008) · Journal of Neurology · doi:10.1007/s00415-008-1002-8 · Cited by 255 · cited 1×
“evidence implicating plasma cells and innate immunity in progressive disease [2].”
BackgroundBLOOD-BRAIN BARRIER DAMAGE IN ACUTE MULTIPLE SCLEROSIS PLAQUES: AN IMMUNOCYTOLOGICAL STUDY
GAY, D., & ESIRI, M. (1991) · Brain · doi:10.1093/brain/114.1.557 · Cited by 239
Gasque, P., Singhrao, S. K., Neal, J. W., Götze, O., & Morgan, B. P. (1997) · Europe PMC (PubMed Central) · Cited by 234
Self-citationGasque, P., Singhrao, S. K., Neal, J. W., Wang, P., Sayah, S., Fontaine, M., & Morgan, B. P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3543 · Cited by 207
Self-citationMead, R. J., Singhrao, S. K., Neal, J. W., Lassmann, H., & Morgan, B. P. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.1.458 · Cited by 198
Self-citationClark, S. J., Perveen, R., Hakobyan, S., Morgan, B. P., Sim, R. B., Bishop, P. N., & Day, A. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.103986 · Cited by 188 · cited 1×
“The functional consequences and relevance to disease progression of this remain to be ascertained; however, in age-related macular degeneration (AMD), differential binding of the fH-Tyr402His variants in retina has been demonstrated and proposed as the mechanism by which fH-His402 is risk for AMD [26].”
BackgroundSelf-citationIMMUNOCYTOCHEMICAL LOCALIZATION OF THE TERMINAL COMPLEMENT COMPLEX IN MULTIPLE SCLEROSIS
COMPSTON, D. A. S., MORGAN, B. P., CAMPBELL, A. K., WILKINS, P., COLE, G., THOMAS, N. D., & JASANI, B. (1989) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1989.tb01231.x · Cited by 185 · cited 2×
“Immune complexes were demonstrated in MS CSF and brain with associated binding of C1q and classical pathway activation [22]; in parallel, it was shown that oligoclonal immunoglobulins were present in CSF in most MS patients [23], the result of intrathecal synthesis [24].”
BackgroundSelf-citationHowell, O. W., Palser, A., Polito, A., Melrose, S., Zonta, B., Scheiermann, C., Vora, A. J., Brophy, P. J., & Reynolds, R. (2006) · Brain · doi:10.1093/brain/awl290 · Cited by 183 · cited 1×
“For immunofluorescence, sections were stained sequentially for complement and cell specific markers at room temperature, according to published protocols [15].”
MethodSelf-citationHow factors secreted from astrocytes impact myelin repair
Moore, C. S., Abdullah, S. L., Brown, A., Arulpragasam, A., & Crocker, S. J. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22482 · Cited by 171 · cited 1×
“The notion of astrocytes contributing to pathological process in MS by enhancement of immune response and disruption of myelin has recently been raised in a number of studies [30,31].”
The immunogenesis of the multiple sclerosis plaque
Lumsden, C. E. (1971) · Brain Research · doi:10.1016/0006-8993(71)90052-7 · Cited by 170 · cited 2×
“Immune complexes were demonstrated in MS CSF and brain with associated binding of C1q and classical pathway activation [22]; in parallel, it was shown that oligoclonal immunoglobulins were present in CSF in most MS patients [23], the result of intrathecal synthesis [24].”
BackgroundImmunoglobulins and complement in postmortem multiple sclerosis tissue
Barnett, M. H., Parratt, J. D. E., Cho, E., & Prineas, J. W. (2009) · Annals of Neurology · doi:10.1002/ana.21524 · Cited by 165 · cited 2×
“Myelin staining for complement proteins has been suggested to be a non-specific feature [12]; however, using double immunolabelling we found complement markers co-localized in areas of degenerating myelin and damaged axons in MS sections (Figures 4 and 5), implicating complement in axonal and myelin injury in and arou…”
BackgroundVanguri, P., Koski, C. L., Silverman, B., & Shin, M. L. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.10.3290 · Cited by 155 · cited 1×
“Even in the absence of antibody, the classical pathway can be triggered by C1q directly binding damaged myelin [25].”
BackgroundC3-dependent mechanism of microglial priming relevant to multiple sclerosis
Ramaglia, V., Hughes, T. R., Donev, R. M., Ruseva, M. M., Wu, X., Huitinga, I., Baas, F., Neal, J. W., & Morgan, B. P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111924109 · Cited by 151
Self-citationLassmann, H. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01189.x · Cited by 120 · cited 2×
“MS lesions were classified as either classical active (profound inflammation with microglia and macrophages containing myelin degradation products) or slowly expanding (central profound axonal loss with loss of macrophages, with a rim of activated microglia and moderate inflammation) [14].”
BackgroundComplement in multiple sclerosis: its role in disease and potential as a biomarker
Ingram, G., Hakobyan, S., Robertson, N. P., & Morgan, B. P. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2008.03830.x · Cited by 110 · cited 1×
“A role for the complement system in MS has been established and is reviewed in Ingram 2010 [3].”
BackgroundSelf-citationDetection of complement activation using monoclonal antibodies against C3d
Thurman, J. M., Kulik, L. N., Orth, H. N., Wong, M., Renner, B., Sargsyan, S. A., Mitchell, L. M., Hourcade, D. E., Hannan, J. P., Kovacs, J. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65861 · Cited by 98 · cited 1×
“Imaging complement activation using labelled antibodies or ligands to target activation products is a rapidly evolving concept that might find particular relevance in MS and other CNS diseases [34,35].”
BackgroundComplement regulator factor H as a serum biomarker of multiple sclerosis disease state
Ingram, G., Hakobyan, S., Hirst, C. L., Harris, C. L., Pickersgill, T. P., Cossburn, M., Loveless, S., Robertson, N. P., & Morgan, B. P. (2010) · Brain · doi:10.1093/brain/awq085 · Cited by 96
Self-citationSystemic complement profiling in multiple sclerosis as a biomarker of disease state
Ingram, G., Hakobyan, S. A., Hirst, C. L., Harris, C. L., Loveless, S., Mitchell, J., Pickersgill, T., Robertson, N. P., & Morgan, B. P. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512438238 · Cited by 81
Self-citationKira, J. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.08.043 · Cited by 60 · cited 1×
“Complementmediated astrocytic impairment was recently described in neuromyelitis optica [28]; our findings imply that this may also be a feature of progressive MS.”
BackgroundImmunofluorescence study of brain plaques from two patients with multiple sclerosis
Woyciechowska, J., & Brzosko, W. (1977) · Neurology · doi:10.1212/wnl.27.7.620 · Cited by 57 · cited 1×
“Immune complexes were demonstrated in MS CSF and brain with associated binding of C1q and classical pathway activation [22]; in parallel, it was shown that oligoclonal immunoglobulins were present in CSF in most MS patients [23], the result of intrathecal synthesis [24].”
BackgroundCerebrospinal fluid C9 in demyelinating disease
Compston, D. A. S., Morgan, B. P., Oleesky, D. A., Fifield, R., & Campbell, A. K. (1986) · Neurology · doi:10.1212/wnl.36.11.1503 · Cited by 50 · cited 2×
“Immune complexes were demonstrated in MS CSF and brain with associated binding of C1q and classical pathway activation [22]; in parallel, it was shown that oligoclonal immunoglobulins were present in CSF in most MS patients [23], the result of intrathecal synthesis [24].”
BackgroundSelf-citationMicroarrays - The Challenge of Preparing Brain Tissue Samples
Soverchia, L., Ubaldi, M., Leonardi‐Essmann, F., Ciccocioppo, R., & Hardiman, G. (2004) · Addiction Biology · doi:10.1080/13556210412331327803 · Cited by 23 · cited 1×
“Positive control tissue sections for testing the anticomplement antibodies comprised arrayed fixed tissue sections [16] from renal biopsies taken from glomerulonephritis patients and myocardium from a patient with myocarditis due to adenovirus; all antibodies positively labelled these sections using the described prot…”
MethodDiagnostic criteria for primary progressive mutiple sclerosis: a position paper.
(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2 · cited 1×
“Pathological heterogeneity and heterogeneity of complement staining in MS lesions was described by Lucchinetti and colleagues; they proposed four distinct patterns of MS lesions with only 50% of patients showing complement immunolabelling, limited in their study to TCC immunolabelling using the mAb B7, also used in ou…”
Method
Cited by
Werneburg, S., Jung, J., Kunjamma, R. B., Ha, S.-K., Luciano, N. J., Willis, C. M., Gao, G., Biscola, N. P., Havton, L. A., Crocker, S. J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.004 · Cited by 440
Clusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies
Foster, E. M., Dangla-Valls, A., Lovestone, S., Ribe, E. M., & Buckley, N. J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00164 · Cited by 381
Complement in neurological disorders and emerging complement-targeted therapeutics
Dalakas, M. C., Alexopoulos, H., & Spaeth, P. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0400-0 · Cited by 363
The good, the bad, and the opportunities of the complement system in neurodegenerative disease
Schartz, N. D., & Tenner, A. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02024-8 · Cited by 286
Nutrition Facts in Multiple Sclerosis
Riccio, P., & Rossano, R. (2015) · ASN Neuro · doi:10.1177/1759091414568185 · Cited by 230
Metadata
- Authors
- Ingram, G., Loveless, S., Howell, O. W., Hakobyan, S., Dancey, B., Harris, C. L., Robertson, N. P., Neal, J. W., & Morgan, B. P.
- Venue
- Acta Neuropathologica Communications
- Published
- 2014-05-09
- Volume
- 2
- Issue
- 1
- Pages
- 53-53
- ISSN
- 2051-5960 (ISSN-L)
- OpenAlex
- W2114062831
- Cited by
- 177
- References
- 35
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.